¥13.34 -0.64   ( -4.58%)
前日收盘:13.98 当日成交量(股):4.27万 当日最高:14.01 总股本:4190.40万
当日开盘:14.00 当日成交额(元):57.71万 当日最低:13.33 流通股本:
市盈率(动/静):0/0 市净率:0 市销率:0 总市值:5.86亿
52周最高:20.48 52周最低:13.33 转让方式: 单位:美元
$Unity Biotechnology(UBX)$
  • 还可以输入
  • 20016

Unity Biotechnology(UBX) 05月21日 03时20分

新闻 UNITY Biotechnology, Inc. Appoints Camille Landis as Senior Vice President of Corporate Development
SAN FRANCISCO, May 14, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, ......  url.vc.watch/ft57
查看全文

Unity Biotechnology(UBX) 05月12日 19时07分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:NELSEN ROBERT
公告日:2018-05-07, 内部交易人:NELSEN ROBERT, 与发行人关系:/董事/10%持股人/, 操作:衍生证券转换(C),2030625(股)Common Stock,均价$; 操作:衍生证券转换(C),4228432(股)Common Stock,均价$; 操作:衍生证券转换(C),2067160(股)Common Stock,均价$; 操作:衍生证券转换(C),1486745(股)Common Stock,均价$; 操作:衍生证券转换(C),195672(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022050, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022050/0001140361-18-022050-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时07分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Goeltz II Robert C.
公告日:2018-05-07, 内部交易人:Goeltz II Robert C., 与发行人关系:Chief Financial Officer/高管/, 操作:衍生证券转换(C),1630(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022049, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022049/0001140361-18-022049-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时07分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:BERNS PAUL L
公告日:2018-05-07, 内部交易人:BERNS PAUL L, 与发行人关系:/董事/, 操作:衍生证券转换(C),3261(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022048, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022048/0001140361-18-022048-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时07分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:David Nathaniel E
公告日:2018-05-07, 内部交易人:David Nathaniel E, 与发行人关系:President/董事/高管/, 操作:衍生证券转换(C),1074032(股)Common Stock,均价$; 操作:衍生证券转换(C),222148(股)Common Stock,均价$; 操作:衍生证券转换(C),1630(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022047, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022047/0001140361-18-022047-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Burow Kristina
公告日:2018-05-07, 内部交易人:Burow Kristina, 与发行人关系:/董事/, 操作:衍生证券转换(C),2030625(股)Common Stock,均价$; 操作:衍生证券转换(C),4228432(股)Common Stock,均价$; 操作:衍生证券转换(C),2067160(股)Common Stock,均价$; 操作:衍生证券转换(C),1486745(股)Common Stock,均价$; 操作:衍生证券转换(C),195672(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022046, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022046/0001140361-18-022046-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Leonard Keith R
公告日:2018-05-07, 内部交易人:Leonard Keith R, 与发行人关系:Chief Executive Officer/董事/高管/, 操作:衍生证券转换(C),383475(股)Common Stock,均价$; 操作:衍生证券转换(C),148448(股)Common Stock,均价$; 操作:衍生证券转换(C),1630(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022045, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022045/0001140361-18-022045-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Dananberg Jamie
公告日:2018-05-07, 内部交易人:Dananberg Jamie, 与发行人关系:Chief Medical Officer/高管/, 操作:衍生证券转换(C),74048(股)Common Stock,均价$; 操作:衍生证券转换(C),1630(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022044, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022044/0001140361-18-022044-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:BYBEE CLINTON
公告日:2018-05-07, 内部交易人:BYBEE CLINTON, 与发行人关系:/10%持股人/, 操作:衍生证券转换(C),2030625(股)Common Stock,均价$; 操作:衍生证券转换(C),4228432(股)Common Stock,均价$; 操作:衍生证券转换(C),2067160(股)Common Stock,均价$; 操作:衍生证券转换(C),1486745(股)Common Stock,均价$; 操作:衍生证券转换(C),195672(股)Common Stock,均价$; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-07, SEC Accession No. 0001140361-18-022043, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118022043/0001140361-18-022043-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Tompkins Tamara
公告日:2018-05-04, 内部交易人:Tompkins Tamara, 与发行人关系:Corporate Secretary and GC/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021826, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021826/0001140361-18-021826-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:NELSEN ROBERT
公告日:2018-05-04, 内部交易人:NELSEN ROBERT, 与发行人关系:/董事/10%持股人/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021823, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021823/0001140361-18-021823-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时06分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Goeltz II Robert C.
公告日:2018-05-04, 内部交易人:Goeltz II Robert C., 与发行人关系:Chief Financial Officer/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021820, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021820/0001140361-18-021820-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时05分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:David Nathaniel E
公告日:2018-05-04, 内部交易人:David Nathaniel E, 与发行人关系:President/董事/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021817, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021817/0001140361-18-021817-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时05分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Burow Kristina
公告日:2018-05-04, 内部交易人:Burow Kristina, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021815, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021815/0001140361-18-021815-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时05分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Leonard Keith R
公告日:2018-05-04, 内部交易人:Leonard Keith R, 与发行人关系:Chief Executive Officer/董事/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021813, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021813/0001140361-18-021813-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时05分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Dananberg Jamie
公告日:2018-05-04, 内部交易人:Dananberg Jamie, 与发行人关系:Chief Medical Officer/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021811, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021811/0001140361-18-021811-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时05分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:COOPER GRAHAM K
公告日:2018-05-04, 内部交易人:COOPER GRAHAM K, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021810, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021810/0001140361-18-021810-index.htm $Unity Biotechnology(UBX)$
查看全文

Unity Biotechnology(UBX) 05月12日 19时05分

公告 Unity Biotechnology, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Marquess Dan
公告日:2018-05-04, 内部交易人:Marquess Dan, 与发行人关系:Chief Scientific Officer/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-05-02, SEC Accession No. 0001140361-18-021808, File:https://www.sec.gov/Archives/edgar/data/1463361/000114036118021808/0001140361-18-021808-index.htm $Unity Biotechnology(UBX)$
查看全文
  • 首页 上一页 1 2 3 下一页 尾页  每页20条/共51